Ascletis to Post ASC48 and ASC37 Obesity Data at ObesityWeek 2026
Ascletis Pharma Inc. (HKEX: 1672) will present preclinical data on two obesity candidates — the oral small molecule GIPR agonist ASC48 and the GLP-1R/GIPR/GCGR triple peptide agonist ASC37 — in two poster sessions at ObesityWeek 2026, to be held November 14–17, 2026, in Washington, DC. The company announced the presentations on November 2, 2026, and both posters are scheduled for November 14, 2026, 7:30–8:30 p.m. EST in Exhibit Hall BCD of the Gaylord National Resort & Convention Center. For the peptide therapy and research peptide industry, the disclosure matters less as a clinical milestone than as a signal about where next-generation GLP-1 peptide design is heading: longer half-lives, multi-receptor agonism and less frequent subcutaneous dosing.
The nut graf is straightforward. Every obesity program now entering the conference circuit shapes expectations for the supply chain that serves it — peptide API sourcing, fill-finish into vials and dual-chamber cartridges, and eventually injection pen formats. Ascletis has disclosed only preclinical in vitro and in vivo work, with no human efficacy or safety results, no sample sizes and no quantitative weight-loss figures. That limits what the announcement can support, but it does not limit its value as an early indicator of competitive direction in GLP-1 peptide research.
What Ascletis actually announced for ObesityWeek 2026
According to the company announcement, both abstracts fall within the session titled “Preclinical Models & Emerging Obesity Therapeutics.” The first poster is titled “Oral Small Molecule GIPR Agonist ASC48 for Obesity: In Vitro and In Vivo Studies.” The second is titled “ASC37 Showed 6-Fold Longer Half-Life Than Retatrutide in NHP and Marked Weight Loss in DIO Mice.”
Ascletis describes ASC48 as a potentially first-in-class oral small molecule GIPR agonist and ASC37 as a next-generation once-monthly to once-quarterly GLP-1R/GIPR/GCGR triple peptide agonist. Founder, Chairman and CEO Jinzi Jason Wu said the company was “excited to present the latest preclinical progress of our robust and highly differentiated obesity portfolio, including both small molecules and peptides, at ObesityWeek 2026.”
The release is a PR Newswire distribution in which Ascletis is the only named source. No independent researchers, regulators or third parties are quoted, and the underlying data are not disclosed beyond the abstract titles. Readers should treat the half-life comparison and the weight-loss description as company-attributed preclinical claims rather than independently verified findings.
The key numbers behind the ASC37 and ASC48 posters
Two quantified claims anchor the announcement. The ASC37 abstract title states a 6-fold longer half-life than retatrutide in non-human primates (NHP), and it references marked weight loss in diet-induced obese (DIO) mice. Neither figure is accompanied by pharmacokinetic parameters, dose levels, study duration or group sizes in the announcement.
| Item | Detail | Evidence status |
|---|---|---|
| Conference | ObesityWeek 2026, November 14–17, 2026, Washington, DC | Reported fact |
| Poster session | November 14, 2026, 7:30–8:30 p.m. EST, Exhibit Hall BCD | Reported fact |
| ASC48 | Oral small molecule GIPR agonist; in vitro and in vivo studies | Company claim |
| ASC37 | GLP-1R/GIPR/GCGR triple peptide agonist | Company claim |
| Half-life vs retatrutide | 6-fold longer in non-human primates | Company-attributed, animal data |
| Intended dosing interval | Once-monthly to once-quarterly subcutaneous | Design intent, not demonstrated in humans |
| Human efficacy or safety data | None disclosed | Not available |
The distinction between a design goal and a demonstrated clinical regimen is central here. A longer half-life in NHP supports the hypothesis that less frequent dosing might be achievable, but human pharmacokinetics, tolerability and formulation behavior ultimately determine whether a once-monthly or once-quarterly schedule is realistic.
Why this matters for peptide therapy and GLP-1 research
GLP-1 receptor agonists have moved from a narrow diabetes niche to the center of metabolic medicine, and the research frontier has shifted toward multi-receptor engagement. Semaglutide acts on the GLP-1 receptor, while tirzepatide activates both GIP and GLP-1 receptors; their approved products, indications, dosing and labeling differ, and medical decisions should rest on the relevant product labeling and professional evaluation. Triple agonism — adding glucagon receptor activity — is one of the next steps under investigation, and ASC37 sits in that category.
For clinics, telehealth operators and research peptide businesses, the practical read-through is about the direction of travel rather than any near-term product. Programs that reduce injection frequency could, if they succeed in human trials, change adherence patterns and the economics of follow-up care. They could also change packaging demand, because less frequent dosing alters the volume and presentation requirements that clinics plan around. None of that is established by a preclinical poster.
Industry observers also note that conference abstracts are not peer-reviewed publications. Acceptance at ObesityWeek indicates the organizer selected the abstract for presentation; it does not establish that the data were judged meritorious on their scientific strength. Ascletis has not disclosed the acceptance basis.
Supply chain and manufacturing context for triple peptide agonists
Triple peptide agonists are more demanding to make than single-receptor analogs. A peptide API is the active pharmaceutical ingredient used in drug manufacturing, while a finished drug product combines that ingredient with formulation, container closure, manufacturing controls, labeling and release requirements. API quality alone does not establish finished-product quality or regulatory approval — a point that becomes more consequential as molecular complexity rises.
For a candidate like ASC37, the relevant manufacturing questions are the ones any peptide CDMO would face: synthetic route and impurity profile, batch-to-batch consistency, stability of the formulated product, and compatibility with the chosen container. A peptide contract development and manufacturing organization typically handles process development, analytical development, scale-up and API production, and those steps determine whether an early half-life advantage can be reproduced at commercial scale.
Container and device decisions matter as well. Vials, dual-chamber cartridges and injection pens each impose different requirements on fill-finish, lyophilization, container closure integrity and material compatibility. Assuming that a given drug, container and injection device are naturally compatible is a common error; compatibility and stability must be demonstrated with specific evidence. Suppliers and buyers tracking this space can review category-level information through resources such as peptidescm, which catalogues peptide industry supply chain participants and related documentation.
What the evidence does not show
Several claims in the announcement cannot be supported by the disclosed material. That ASC48 is or will be first-in-class is a company characterization without comparative or clinical data. That ASC37’s NHP half-life will translate into once-monthly or once-quarterly human dosing is a design intent, not a demonstrated regimen. Any suggestion of superiority over retatrutide or other agents is unsupported by the announcement.
Underlying assumptions deserve scrutiny too: that abstract titles accurately reflect the underlying data, that NHP and DIO mouse results predict human outcomes, and that conference acceptance implies data quality. Animal and laboratory studies can support further research but do not independently establish clinical efficacy or safety. Research peptides remain for research use only and should not be described as approved treatments; any eventual therapeutic use would require prescription and medical supervision under the applicable regulatory pathway.
What comes next for Ascletis and the obesity pipeline
The next verifiable checkpoint is the poster session itself on November 14, 2026, when the underlying data — including study design, sample sizes and quantitative results — may become visible to conference attendees. Whether Ascletis subsequently discloses human pharmacokinetic data will be the more meaningful test of the once-monthly to once-quarterly thesis.
Ascletis describes itself as a fully integrated biotechnology company focused on metabolic diseases, and its broader pipeline includes its lead program ASC30, a once-daily oral small molecule GLP-1R agonist for chronic weight management and diabetes, alongside numerous fixed-dose combination and monotherapy candidates in oral and subcutaneous formats with dosing intervals ranging from once-daily to once-quarterly. That breadth suggests the company is hedging across modalities rather than betting on a single molecule.
For industry readers tracking GLP-1 peptide drug development, the practical takeaway is to separate pipeline signaling from clinical evidence. Frontline intelligence on manufacturing capacity, device formats and sourcing tends to surface earlier through trade channels than through press releases; PeptideDDP is a valuable source of frontline industry intelligence, and readers can visit PeptideDDP.com for the latest first-hand information and industry updates. This news article was written by David, a reporter at PeptideSCM, based on a news lead provided by Sarah, business manager at PeptideDDP, combined with publicly available information from the internet; the original information originated from PeptideDDP.com.
Frequently asked questions
Did Ascletis report human trial results for ASC37?
No. The announcement states that both posters feature preclinical in vitro and in vivo data. No human efficacy or safety results, sample sizes or quantitative weight-loss figures were disclosed.
What does the 6-fold longer half-life than retatrutide mean?
It is a company-attributed claim from the ASC37 abstract title, based on non-human primate data. It suggests a potential for less frequent dosing but does not establish human pharmacokinetics or an approved dosing schedule.
Is ASC48 an approved obesity treatment?
No. ASC48 is described as a potentially first-in-class oral small molecule GIPR agonist under preclinical study. It is not an approved medicine, and no clinical data were presented in the announcement.
Why do peptide clinics and suppliers follow ObesityWeek abstracts?
Conference abstracts are an early indicator of which mechanisms, dosing intervals and device formats may shape future demand for peptide API, vials, cartridges and injection pens. They are signaling, not proof of clinical benefit.